Compare Gartner Inc (IT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Tango Therapeutics Inc. — how do they compare? Gartner Inc trades at $197.83 (market cap $12.36B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Gartner Inc is far larger — about 3.3× Tango Therapeutics Inc.'s market cap, and Gartner Inc is more actively traded (656,911 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| IT | TNGX | |
|---|---|---|
Market Cap | $12.36B | $3.74B |
Volume | 656,911 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $258.17 | $32.90 |
52-Week Low | $125.68 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $14.11B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $196.96, up 1.47% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, the company maintains robust profitability with 69.63% gross margins and 12% net income margin, though recent cash flow trends show some volatility with negative net cash flow in 2025. Recent news highlights Gartner's leadership position in AI advisory services and strong industry recognition.
The outlook remains positive with AI-driven consulting demand supporting growth, though investors should note the elevated P/B ratio of 160.06 and ongoing fiduciary duty investigation. Analyst consensus suggests moderate upside potential with a $178.14 price target, while technical resistance at $197 presents near-term challenge.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
